Abstract

BackgroundHospital admission is a key cost driver in ABSSSI patients. Data suggest many ABSSSI patients are unnecessarily hospitalized and can be effectively and safely managed as outpatient (OP) at substantially lower cost. ORI a single-dose treatment has the potential to shift care from the inpatient (IP) to the OP setting in selected patients. In phase III trials, a single dose of ORI had comparable efficacy and safety to twice daily VAN for 7–10 days in ABSSSI patients who were treated in OP. Real-world comparative data on outcomes in ABSSSI patients using ORI in OP are limited. This study sought to compare the 30 day hospital admission rates and mean (standard deviation (SD)) healthcare costs among ABSSSI patients who received ORI or VAN as an OP.MethodsRetrospective cohort analysis of ORI and VAN patients in the Truven Health MarketScan® Databases in 2016. Inclusion criteria: age ≥18 years; OP claim for ORI or VAN (index day (d)); a diagnosis of skin infection ≤7 d prior and 3 d after the index day; no IP discharge in 3 d prior to index day; ≥180 d of continuous enrollment prior to index day; ≥60 d of continuous enrollment post index day. Outcomes: 30 d hospital admissions and 30 d total healthcare costs.ResultsIn 2016, 120 and 6,695 patients who received ORI and VAN, respectively, met inclusion criteria. Groups were well balanced at baseline (table). ORI patients had a significantly lower 30 d admission rate vs. VAN patients (5.8% vs. 16.2%, respectively, P = 0.002). Mean (SD) cost 30 d post index were comparable between ORI and VAN patients ($10,096 (8,865) vs. 12,779 (28,773), respectively, P = 0.3).ConclusionResults suggest ORI provides a single-dose alternative to multi-dose VAN for treatment of ABSSSI in OP and may result in lower 30 d hospital admission rates.ORIVANBaseline characteristicsMean (SD) age, years54.9 (16.8)52.8 (16.5)Mean (SD) Deyo Charlson comorbidity index1.3 (1.8)1.5 (2.2)Skin infection Cellulitis/abscess90.0%86.6% Wound infection10.0%14.4% Other skin infections17.5%14.0%Life-threatening condition13.3%12.%Non-life-threatening systemic symptoms14.2%19.1%Hospitalization during baseline43.3%36.1%Prior mean (SD) total healthcare costs$47,354 ($33,567)$35,183 ($74,109)Disclosures T. Lodise, Melinta Therapeutics, Inc.: Consultant, Consulting fee. E. Packnett, Melinta Therapeutics, Inc.: Research Contractor, Research grant. S. Armstrong, The Medicine’s Company: Employee, Salary. M. Redell, Melinta Therapeutics, Inc.: Employee and Shareholder, Salary.

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.